The US Food and Drug Administration will likely continue to use remote inspection alternatives that emerged during the COVID-19 pandemic in a “hybrid approach” with in-person inspections, not in place of them, says assistant commissioner Elizabeth Miller.
How The US FDA’s Inspectional Approach Is Shifting For The Post-Pandemic Era
Agency hints of a “hybrid” future of in-person inspections supplemented by alternative tools like remote interactive evaluations.